186 related articles for article (PubMed ID: 27089054)
21. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
[TBL] [Abstract][Full Text] [Related]
22. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.
Zeng Y; Kakehi Y; Nouh MA; Tsunemori H; Sugimoto M; Wu XX
Prostate; 2009 Feb; 69(3):283-92. PubMed ID: 19025891
[TBL] [Abstract][Full Text] [Related]
24. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer.
Feder-Mengus C; Wyler S; Hudolin T; Ruszat R; Bubendorf L; Chiarugi A; Pittelli M; Weber WP; Bachmann A; Gasser TC; Sulser T; Heberer M; Spagnoli GC; Provenzano M
Eur J Cancer; 2008 Oct; 44(15):2266-75. PubMed ID: 18619832
[TBL] [Abstract][Full Text] [Related]
25. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
26. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
27. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
28. Humoral response profiling reveals pathways to prostate cancer progression.
Taylor BS; Pal M; Yu J; Laxman B; Kalyana-Sundaram S; Zhao R; Menon A; Wei JT; Nesvizhskii AI; Ghosh D; Omenn GS; Lubman DM; Chinnaiyan AM; Sreekumar A
Mol Cell Proteomics; 2008 Mar; 7(3):600-11. PubMed ID: 18077443
[TBL] [Abstract][Full Text] [Related]
29. No Tumor Suppressor Role for
Koseoglu H; Celebi A; Galamiyeva G; Dalay N; Ozkardes H; Buyru N
DNA Cell Biol; 2021 Sep; 40(9):1222-1229. PubMed ID: 34370601
[TBL] [Abstract][Full Text] [Related]
30. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
31. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
32. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
33. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
34. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
35. Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia.
Kawahara R; Recuero S; Nogueira FCS; Domont GB; Leite KRM; Srougi M; Thaysen-Andersen M; Palmisano G
Proteomics; 2019 Nov; 19(21-22):e1900174. PubMed ID: 31576646
[TBL] [Abstract][Full Text] [Related]
36. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
[TBL] [Abstract][Full Text] [Related]
37. Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.
Totten SM; Adusumilli R; Kullolli M; Tanimoto C; Brooks JD; Mallick P; Pitteri SJ
Sci Rep; 2018 Apr; 8(1):6509. PubMed ID: 29695737
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
39. Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3.
Pontes ER; Matos LC; da Silva EA; Xavier LS; Diaz BL; Small IA; Reis EM; Verjovski-Almeida S; Barcinski MA; Gimba ER
Prostate; 2006 Oct; 66(14):1463-73. PubMed ID: 16897729
[TBL] [Abstract][Full Text] [Related]
40. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
Avgeris M; Stravodimos K; Scorilas A
Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
